Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor (NASDAQ:XNCR) selected a 400 microgram-per-kilogram intravenous dose for XmAb819 in Phase 3 trials after observing a 45.5% response rate in kidney cancer. The company plans to discuss accelerated approval with the FDA in 2027 and compare XmAb819 with tivozanib in a confirmatory study. Xencor also expects to report subcutaneous XmAb819 data in 2027.
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 dose and response rate provide a concrete efficacy signal that could accelerate FDA discussions and affect the company's valuation.
Market read
First‑time release of pivotal trial data for a renal‑cancer antibody candidate, likely to move Xencor stock and influence sector sentiment.
What to watch
Regulatory timeline and need for confirmatory Phase 3 data could delay commercialization.
Background
Xencor is a clinical‑stage biopharma developing engineered antibodies; XmAb819 targets advanced clear‑cell renal cell carcinoma.
Ticker impact
Xencor announced its Phase 3 dose of XmAb819 with a 45.5% response rate in kidney cancer, a first report of pivotal trial data.
upward pressure as investors price in promising efficacy data
First disclosure of robust response data in a late‑stage trial is material for a clinical‑stage biotech.
Market effects
May boost sentiment for renal‑cancer biotech peers and antibody‑engineered therapeutics.
Limited to US biotech sector; no broader regional effect.
Relevant to global oncology investors tracking antibody platforms.
Counterpoint
If the data does not translate to overall survival benefit, the hype could fade.
Key entities
- CompanyXencor Inc.
Clinical‑stage biopharma developing XmAb platform.
- ExecutiveBassil Dahiyat
President and CEO of Xencor.
